Rybrevant (amivantamab)
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for Rybrevant (amivantamab), covering 2025-12-18 to 2026-04-13. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies [Phase 1]